公共卫生资源的优化配置是人民健康福祉改善与健康水平提升的重大前提，也是当前中国医改面临的重大挑战。卫生技术评估（HTA）为此提供了科学的解决方法，而偏好研究是HTA中一种重要的价值评估与健康结果测量方法。因此，探究患者在医疗技术收益、风险、成本等关键属性间的权衡，探索中国医患治疗偏好差异，是卫生领域重要的基础研究课题。本研究拟采用新兴Best-worst标度法（BWS）与传统离散选择实验（DCE），以癌症、心血管疾病、疫苗三大防治领域为例，探究中国医患偏好。首先，基于BWS测量患者治疗偏好，完善BWS计量经济模型，优化偏好测量体系；其次，比较BWS与DCE开展偏好测量的信效度与优缺点，进行方法优选；最后，评估不同疾病领域中国医患治疗偏好的一致性与差异。本课题的开展将促进医患沟通，推动以患者为中心医疗服务模式的建立，推进中国医疗领域偏好研究与HTA的发展，为临床与卫生政策的制定提供科学依据

Public health resources optimization allocation serves the basis of the health improvement from the population level, and also is a major challenge to the current healthcare reform in China. The Health Technology Assessment (HTA) provides a scientific solution to this problem, among which preference research is an important branch for medical value assessment and health outcome measurement. Investigating patients’ trade-off between health benefits, risks, costs and other key features of health technologies, exploring the preference differences between patients and healthcare professionals, are therefore of crucial importance in the present China. This research intends to explore the health preferences between patients and healthcare professionals based on the emerging best-worst scaling (BWS) and traditional discrete choice experiment (DCE) in the cases of cancer, cardiovascular disease and vaccination. Firstly, this study will investigate the health preference based on BWS method across different disease areas, and optimize the preference measurement system through different econometric models. Secondly, this study will compare the reliability, validity and concordance of BWS and DCE for eliciting preferences in selected diseases. Finally, this study will evaluate the consistency and differences between the Chinese patients’ and physicians’ preference. The results obtained from this research will promote the effective communication between patients and healthcare professionals, promote the establishment of patient-centered medical service system, and also will promote the development of healthcare preference research in particular and HTA in general, which will provide scientific evidence for the clinical and public health decision making in China.